Acambis gets $1.3M grant for vaccine R&D

28 June 2001

Acambis of the UK has been awarded two grants under the US Department ofDefense's Dual Use Science & Technology program, to the tune of $1.3 million, to support its efforts in developing vaccines to prevent diarrhea caused by enterotoxigenic Escherichia coli and Campylobacter.

Acambis' ETEC vaccine is an orally-administered mixture of five live, attenuated strains, the first of which has already been tested in Phase I trials. The Campylobacter program has just entered preclinical development and is based on a bacterial antigen delivered via Acambis' proprietary live, attenuated Salmonella typhi vector (HolaVax) technology. Orally-active clinical candidates from the latter program are scheduled to enter trials in 2003.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight